SSYNF (Sensyne Health) 3-Year Share Buyback Ratio : 0.00% (As of Oct. 2021)

View and export this data going back to 2019. Start your Free Trial

What is Sensyne Health 3-Year Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Sensyne Health's current 3-Year Share Buyback Ratio was 0.00%.

The historical rank and industry rank for Sensyne Health's 3-Year Share Buyback Ratio or its related term are showing as below:

During the past 4 years, Sensyne Health's highest 3-Year Share Buyback Ratio was 0.00%. The lowest was 0.00%. And the median was 0.00%.

SSYNF's 3-Year Share Buyback Ratio is not ranked ^*
in the Healthcare Providers & Services industry.
Industry Median: -1.9
* Ranked among companies with meaningful 3-Year Share Buyback Ratio only.

Competitive Comparison of Sensyne Health's 3-Year Share Buyback Ratio

For the Health Information Services subindustry, Sensyne Health's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sensyne Health's 3-Year Share Buyback Ratio Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Sensyne Health's 3-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Sensyne Health's 3-Year Share Buyback Ratio falls into.

Save Embed

;

Save Embed

;

Sensyne Health 3-Year Share Buyback Ratio Calculation

This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Sensyne Health (OTCPK:SSYNF) 3-Year Share Buyback Ratio Explanation

A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Sensyne Health 3-Year Share Buyback Ratio Related Terms

Thank you for viewing the detailed overview of Sensyne Health's 3-Year Share Buyback Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Sensyne Health Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Sensyne Health PLC (OTCPK:SSYNF) » Definitions » 3-Year Share Buyback Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

Oxford Science Park, John Eccles House, Robert Robinson Avenue, Oxford, GBR, OX4 4GP

Website

https://www.sensynehealth.com

Sensyne Health PLC develops clinically validated software applications powered by artificial intelligence including prescribed digital therapeutics and hospital systems for clinical care. Its products connect patients, clinicians and researchers, generating large databases of phenotypic data, enabling discovery research and improving patient outcomes. The company's segments include Healthcare and Life Sciences. It generates maximum revenue from the Healthcare segment. Geographically, it derives a majority of revenue from the United Kingdom.